Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Singl...

FDA Drug Recall #D-0130-2023 — Class II — December 22, 2022

Recall Summary

Recall Number D-0130-2023
Classification Class II — Moderate risk
Date Initiated December 22, 2022
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Pine Pharmaceuticals, LLC
Location Tonawanda, NY
Product Type Drugs
Quantity 11,453 vials

Product Description

Epi-Caine, Epinephrine 0.025% Lidocaine HCL 0.75% Solution for Intraocular Injection, 1 ml, Single Dose Vial, Compounded by Pine Pharmaceuticals, 355 Riverwalk Pkwy, Tonawanda, NY 14150. NDC 69194-0948-1

Reason for Recall

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Distribution Pattern

Nationwide to medical facilities.

Lot / Code Information

Lot # 62881, Exp 12/25/2022; 62923, Exp 12/26/2022; 63066, Exp 01/03/2023; 63067, Exp 01/01/2023; 63103, Exp 01/02/2023; 63120, Exp 01/03/2023; 63219, 63226, Exp 01/08/2023; 63263, Exp 01/09/2023; 63380, 63381, Exp 01/15/2023; 63433, Exp 01/16/2023; 63455, Exp 01/17/2023; 63537, Exp 01/22/2023; 63580, Exp 01/23/2023; 63721, Exp 01/29/2023; 63792, Exp 01/31/2023; 63888, Exp 02/05/2023; 63930, Exp 02/06/2023; 63959, Exp 02/07/2023; 64079, Exp 02/13/2023; 64109, Exp 02/14/2023; 64239, Exp 02/21/2023.

Other Recalls from Pine Pharmaceuticals, LLC

Recall # Classification Product Date
D-0059-2024 Class II Lidocaine-phenylephrine 1%-1.5% 1mL Single Dose... Oct 2, 2023
D-0057-2024 Class II Cefuroxime 4mg /0.4 mL (10 mg/mL), 1mL syringe,... Oct 2, 2023
D-0058-2024 Class II Moxifloxacin in Balanced Salt Solution 400 mcg/... Oct 2, 2023
D-0055-2024 Class II Tropi-Phen (Tropicamide 1% phenylephrine HCl 2.... Oct 2, 2023
D-0061-2024 Class II Calcium chloride Solution for Intravenous Injec... Oct 2, 2023

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.